Aktuelle Behandlungsstrategien bei Hodentumoren im klinischen Stadium I

详细信息    查看全文

• 作者：Prof. Dr. Mark Schrader ; Friedemann Zengerling
• 关键词：SchlüsselwörterKeimzelltumoren ; Carboplatin ; Monotherapie ; Surveillance ; Patientenpräferenz ; Adjuvante Therapie
• 刊名：Der Onkologe
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：23
• 期：2
• 页码：97-101
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Oncology;
• 出版者：Springer Medizin
• ISSN：1433-0415
• 卷排序：23

文摘

BackgroundThe therapy of clinical stage I testicular cancer has radically changed during the last few years. Some authors demand that adjuvant therapy in clinical stage I is omitted regardless of the risk profile of the tumor. This approach to germ cell tumors is underlined by several studies, which show an excellent survival rate regarding surveillance only strategies. In general, in this stage a reduction in therapy is becoming more frequent.